Physician profile
Inna Dilman
NPI 1245586627
$2,209.03
in general payments reported to CMS, 2019-2025
24 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $176 · 2023: $454 · 2024: $634 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.24 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $239.41 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $214.59 | 2024-2025 | Qelbree |
| Pfizer INC. | $213.06 | 2021-2022 | |
| Alkermes, INC. | $119.93 | 2025 | Lybalvi |
| Amgen INC. | $113.95 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.38 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $107.00 | 2023 | Quviviq |
| Novo Nordisk INC | $95.94 | 2021-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $75.17 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $59.51 | 2022-2023 | Farxiga |
| Sanofi Pasteur INC. | $47.17 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $43.48 | 2022 | |
| Glaxosmithkline, LLC. | $36.37 | 2023 | Trelegy Ellipta |
| Abbott Laboratories | $32.02 | 2021-2025 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $26.55 | 2024 | Loreev Xr |
| Boston Scientific Corporation | $16.53 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.35 | 2021 | |
| Lilly USA, LLC | $14.75 | 2023 | Mounjaro |
| Exact Sciences Corporation | $14.62 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $14.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.54 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.74 | 2023 | Seglentis |
| Esperion Therapeutics, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Dilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.